168 reports of this reaction
1.9% of all CLOMIPRAMINE HYDROCHLORIDE reports
#8 most reported adverse reaction
SUICIDE ATTEMPT is the #8 most commonly reported adverse reaction for CLOMIPRAMINE HYDROCHLORIDE, manufactured by SpecGx LLC. There are 168 FDA adverse event reports linking CLOMIPRAMINE HYDROCHLORIDE to SUICIDE ATTEMPT. This represents approximately 1.9% of all 8,892 adverse event reports for this drug.
Patients taking CLOMIPRAMINE HYDROCHLORIDE who experience suicide attempt should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
SUICIDE ATTEMPT is a less commonly reported adverse event for CLOMIPRAMINE HYDROCHLORIDE, but still significant enough to appear in the safety profile.
In addition to suicide attempt, the following adverse reactions have been reported for CLOMIPRAMINE HYDROCHLORIDE:
The following drugs have also been linked to suicide attempt in FDA adverse event reports:
SUICIDE ATTEMPT has been reported as an adverse event in 168 FDA reports for CLOMIPRAMINE HYDROCHLORIDE. This does not prove causation, but indicates an association observed in post-market surveillance data.
SUICIDE ATTEMPT accounts for approximately 1.9% of all adverse event reports for CLOMIPRAMINE HYDROCHLORIDE, making it a notable side effect.
If you experience suicide attempt while taking CLOMIPRAMINE HYDROCHLORIDE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.